

Michael L Friedlander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5500656/publications.pdf>

Version: 2024-02-01

320
papers

33,594
citations

9786

73
h-index

4117

175
g-index

329
all docs

329
docs citations

329
times ranked

27901
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
2	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	27.0	1,854
3	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with <i>BRCA1</i> or <i>BRCA2</i> mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 245-251.	13.7	1,596
4	Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine, 2012, 366, 1382-1392.	27.0	1,595
5	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with <i>BRCA1</i> or <i>BRCA2</i> mutations and advanced breast cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 235-244.	13.7	1,584
6	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation. Journal of Clinical Oncology, 2015, 33, 244-250.	1.6	1,473
7	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a <i>BRCA1/2</i> mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
8	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by <i>BRCA</i> status in a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 852-861.	10.7	1,237
9	Whole-genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	27.8	1,206
10	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
11	<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	1.6	1,018
12	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology, 2009, 27, 1419-1425.	1.6	645
13	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.	27.0	627
14	Chemotherapy-induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437.	329.8	547
15	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecological Cancer, 2011, 21, 419-423.	2.5	500
16	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 87-97.	10.7	491
17	Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2012, 30, 372-379.	1.6	445
18	Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry, 1985, 6, 327-333.	1.8	427

#	ARTICLE	IF	CITATIONS
19	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1579-1589.	10.7	380
20	2010 Gynecologic Cancer InterGroup (GCIg) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 750-755.	2.5	361
21	Secondary Somatic Mutations Restoring <i>hRAD51C</i> and <i>hRAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	9.4	310
22	Platinum resistant ovarian cancer: What is it, who to treat and how to measure benefit?. <i>Gynecologic Oncology</i> , 2014, 133, 624-631.	1.4	305
23	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3374-3382.	1.6	302
24	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 353-367.	1.2	295
25	Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1686-1691.	2.5	290
26	Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. <i>Nature Genetics</i> , 2000, 24, 197-200.	21.4	260
27	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , 2016, 140, 199-203.	1.4	252
28	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
29	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 32-37.	1.4	228
30	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	7.0	217
31	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	10.7	215
32	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1269-1282.	10.7	207
33	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	2.3	205
34	Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer. <i>Oncologist</i> , 2002, 7, 342-347.	3.7	203
35	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , 2009, 132, 2712-2723.	7.6	198
36	The Y Deletion <i>gr/gr</i> and Susceptibility to Testicular Germ Cell Tumor. <i>American Journal of Human Genetics</i> , 2005, 77, 1034-1043.	6.2	197

#	ARTICLE	IF	CITATIONS
37	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , 2005, 32, 51-60.	2.2	194
38	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S118-29.	2.3	194
39	The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 215-223.	2.5	188
40	Clinical Trials in Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 771-775.	2.5	186
41	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/COG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1721-1731.	10.7	172
42	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.	3.7	171
43	It's Now or Never: Fertility-Related Knowledge, Decision-Making Preferences, and Treatment Intentions in Young Women With Breast Cancer—An Australian Fertility Decision Aid Collaborative Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1670-1677.	1.6	171
44	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	1.6	154
45	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.	1.6	153
46	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	1.6	148
47	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	2.3	145
48	Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk. <i>Journal of Clinical Oncology</i> , 2004, 22, 1315-1327.	1.6	140
49	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. <i>Human Molecular Genetics</i> , 2006, 15, 443-451.	2.9	138
50	Breast Cancer Prognosis in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 19-26.	1.6	134
51	The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: A qualitative study. <i>Psycho-Oncology</i> , 2003, 12, 500-511.	2.3	133
52	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 1075-1085.	6.4	133
53	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	7.0	126
54	10-year performance of four models of breast cancer risk: a validation study. <i>Lancet Oncology</i> , The, 2019, 20, 504-517.	10.7	116

#	ARTICLE	IF	CITATIONS
55	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1805-1812.	1.6	114
56	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2018, 19, 1126-1134.	10.7	113
57	Intention to Undergo Prophylactic Bilateral Mastectomy in Women at Increased Risk of Developing Hereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2250-2257.	1.6	112
58	The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. <i>Human Reproduction</i> , 2017, 32, 1033-1045.	0.9	110
59	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. <i>Cancer Research</i> , 2012, 72, 4060-4073.	0.9	100
60	Agreement Between Self-Reported Breast Cancer Treatment and Medical Records in a Population-Based Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2005, 23, 4679-4686.	1.6	99
61	Impact of oxaliplatin-induced neuropathy: a patient perspective. <i>Supportive Care in Cancer</i> , 2012, 20, 2959-2967.	2.2	93
62	Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. <i>Gynecologic Oncology</i> , 2014, 132, 690-697.	1.4	92
63	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers. <i>JAMA Oncology</i> , 2018, 4, 522.	7.1	92
64	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	10.7	87
65	Uterine papillary serous carcinoma. A clinical study. <i>Cancer</i> , 1995, 75, 2239-2243.	4.1	86
66	The role of BRCA mutation testing in determining breast cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 708-717.	27.6	85
67	If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1333-1344.	3.7	84
68	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , 2016, 31, 1126-1132.	0.9	84
69	Oxaliplatin and Axonal Na ⁺ Channel Function <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2006, 12, 4481-4484.	7.0	82
70	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
71	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
72	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	2.6	79

#	ARTICLE	IF	CITATIONS
73	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
74	Guidelines for the treatment of recurrent and metastatic cervical cancer. <i>Oncologist</i> , 2002, 7, 342-7.	3.7	77
75	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine) triphosphate (ATP) levels. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
76	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
77	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology</i> , The, 2015, 16, e43-e52.	10.7	72
78	Current management of epithelial ovarian carcinoma: A review. <i>Journal of Surgical Oncology</i> , 2000, 19, 11-19.	1.4	70
79	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	2.3	70
80	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , 2011, 43, 367-374.	2.2	69
81	Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 648-654.	2.5	69
82	Attitudes toward Prophylactic Oophorectomy and Screening Utilization in Women at Increased Risk of Developing Hereditary Breast/Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 75, 122-129.	1.4	68
83	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2140-2150.	1.6	68
84	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	1.6	64
85	Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 699-705.	1.6	63
86	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
87	Dose Effects of Oxaliplatin on Persistent and Transient Na ⁺ Conductances and the Development of Neurotoxicity. <i>PLoS ONE</i> , 2011, 6, e18469.	2.5	61
88	What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. <i>Lancet Oncology</i> , The, 2005, 6, 581-588.	10.7	59
89	The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 126-135.	1.2	59
90	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , 2014, 201, 283-288.	1.7	56

#	ARTICLE	IF	CITATIONS
91	Assessing Health-Related Quality of Life in Gynecologic Oncology. International Journal of Gynecological Cancer, 2010, 20, 664-684.	2.5	53
92	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. British Journal of Cancer, 2016, 115, 1313-1320.	6.4	52
93	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Research, 2018, 20, 132.	5.0	51
94	Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology, 2009, 27, 5109-5114.	1.6	50
95	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology, 2012, 30, 5001-5001.	1.6	50
96	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 2019, 154, 531-538.	1.4	49
97	Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Research and Treatment, 2000, 59, 101-111.	2.5	48
98	Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 2009, 45, 3262-3270.	2.8	48
99	Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer, 2005, 4, 105-113.	1.9	47
100	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecologic Oncology, 2016, 140, 443-449.	1.4	47
101	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).. Journal of Clinical Oncology, 2019, 37, 5501-5501.	1.6	46
102	The frequency of founder mutations in theBRCA1,BRCA2, andAPC genes in australian Ashkenazi Jews. Cancer, 2001, 92, 440-445.	4.1	45
103	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. Journal of Pain and Symptom Management, 2017, 54, 74-84.	1.2	45
104	The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. Breast, 2008, 17, 436-440.	2.2	44
105	A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 269-285.	3.2	44
106	Analysis of loss of heterozygosity andKRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. , 1997, 18, 75-83.		42
107	Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Research, 2008, 10, 216.	5.0	42
108	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	1.6	42

#	ARTICLE	IF	CITATIONS
109	Development and Pilot Testing of a Fertility Decision Aid for Young Women Diagnosed with Early Breast Cancer. <i>Breast Journal</i> , 2011, 17, 112-114.	1.0	42
110	Do <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3920-3925.	1.6	42
111	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in <i>BRCA1</i> / <i>BRCA2</i> metastatic breast cancer: design and rationale. <i>Future Oncology</i> , 2017, 13, 307-320.	2.4	41
112	Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. <i>Quality of Life Research</i> , 2018, 27, 59-74.	3.1	40
113	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a <i>BRCA</i> mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 632-642.	10.7	40
114	Communication and Information Needs of Women Diagnosed With Ovarian Cancer Regarding Treatment-Focused Genetic Testing. <i>Oncology Nursing Forum</i> , 2013, 40, 275-283.	1.2	39
115	Preventing breast and ovarian cancers in high-risk <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Medical Journal of Australia</i> , 2013, 199, 680-683.	1.7	39
116	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015, 136, 18-24.	1.4	39
117	Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity. <i>Clinical Colorectal Cancer</i> , 2006, 6, 146-151.	2.3	38
118	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 133, 245-254.	2.4	38
119	Analysis of the <i>DND1</i> gene in men with sporadic and familial testicular germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 247-252.	2.8	37
120	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. <i>Quality of Life Research</i> , 2016, 25, 2457-2465.	3.1	37
121	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020, 80, 116-125.	0.9	37
122	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019, 25, 3962-3973.	7.0	36
123	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	1.4	35
124	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5503-LBA5503.	1.6	35
125	Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. <i>Gynecologic Oncology</i> , 2007, 106, 44-51.	1.4	33
126	Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1338-1342.	6.3	33

#	ARTICLE	IF	CITATIONS
127	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	2.9	33
128	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials. JAMA Network Open, 2020, 3, e2011809.	5.9	33
129	Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1792-1797.	2.5	32
130	Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 323-331.	1.1	32
131	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 126-138.	2.8	32
132	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. European Journal of Cancer, 2017, 78, 133-138.	2.8	31
133	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2019, 174, 271-278.	2.5	31
134	Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 2014, 24, 865-873.	2.5	30
135	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 2006, 6, 297-304.	2.3	29
136	Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 2010, 120, 715-723.	2.5	29
137	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. Gynecologic Oncology, 2015, 136, 37-42.	1.4	29
138	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Supportive Care in Cancer, 2018, 26, 4133-4142.	2.2	29
139	Symptom Control in Patients With Recurrent Ovarian Cancer: Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, S44-S48.	2.5	29
140	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. Oncologist, 2018, 23, 203-213.	3.7	28
141	Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 704-716.	2.5	27
142	Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?. Journal of Clinical Oncology, 2013, 31, 2362-2362.	1.6	27
143	Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research, 2019, 21, 128.	5.0	27
144	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).. Journal of Clinical Oncology, 2013, 31, 5505-5505.	1.6	27

#	ARTICLE	IF	CITATIONS
145	The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions. International Journal of Gynecological Cancer, 2011, 21, 1.	2.5	26
146	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) â€“ Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology, 2018, 148, 36-41.	1.4	26
147	OVQUEST â€“ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecologic Oncology, 2019, 155, 126-134.	1.4	26
148	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
149	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecologic Oncology, 2004, 93, 417-421.	1.4	23
150	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From <i>BRCA1/2</i>-Associated Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4224-4226.	1.6	23
151	How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer, 2012, 12, 320.	2.6	23
152	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993.	2.6	23
153	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes, 2017, 1, 5.	1.9	23
154	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. Journal of Geriatric Oncology, 2020, 11, 508-514.	1.0	23
155	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, 2017, 8, 47154-47160.	1.8	23
156	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. Oncotarget, 2016, 7, 19840-19849.	1.8	23
157	Oxaliplatin-Induced Lhermitteâ€™s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Oncology, 2009, 77, 342-348.	1.9	21
158	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Familial Cancer, 2009, 8, 451-456.	1.9	21
159	Dry eyes and Als: If you don't ask you won't find out. Breast, 2015, 24, 694-698.	2.2	21
160	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 122-129.	1.4	21
161	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
162	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 2019, 58, 1023-1032.	1.2	21

#	ARTICLE	IF	CITATIONS
163	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 167-176.	2.5	20
164	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 179-186.	1.4	20
165	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3013-3013.	1.6	20
166	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5533-5533.	1.6	20
167	Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i> 2013;(suppl; abstr 3). <i>Chinese Clinical Oncology</i> , 2014, 3, 6.	1.2	20
168	Cancer Risk Management Practices of Noncarriers Within<i>BRCA1/2</i>Mutationâ€“Positive Families in the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 225-232.	1.6	19
169	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. <i>Experimental Neurology</i> , 2011, 227, 120-127.	4.1	18
170	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	1.4	18
171	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e86.	2.2	18
172	Paragon (ANZGOG-0903). <i>International Journal of Gynecological Cancer</i> , 2017, 27, 900-906.	2.5	17
173	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 99-106.	2.8	17
174	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	6.4	17
175	Insomnia and its association with quality of life in women with ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 760-768.	1.4	17
176	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 374-381.	1.4	17
177	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , 2021, 163, 41-49.	1.4	17
178	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , 2021, 163, 72-78.	1.4	17
179	Olaparib monotherapy in patients with advanced cancer and a germ-line <i>BRCA1/2</i> mutation: An open-label phase II study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11024-11024.	1.6	17
180	Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. <i>Lancet</i> , The, 2001, 357, 1767-1768.	13.7	16

#	ARTICLE	IF	CITATIONS
181	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 359.	2.2	16
182	A healthy lifestyle and survival among women with ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 3361-3369.	5.1	16
183	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 223-232.	2.9	16
184	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2021, 5, 1151-1159.	3.0	16
185	Malignant Transformation Within Ovarian Dermoid Cysts. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 75-81.	2.5	15
186	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. <i>Supportive Care in Cancer</i> , 2016, 24, 2627-2634.	2.2	15
187	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer – a population-based study. <i>Acta Oncologica</i> , 2016, 55, 226-233.	1.8	15
188	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	4.1	15
189	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	1.4	15
190	Carboplatin Dosing in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	14
191	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. <i>Gynecologic Oncology</i> , 2018, 150, 527-533.	1.4	14
192	A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1239-1242.	2.5	14
193	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 229-232.	2.5	14
194	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021, 127, 2432-2441.	4.1	14
195	Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5507-5507.	1.6	14
196	Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. <i>Journal of Clinical Neuroscience</i> , 2006, 13, 595-598.	1.5	13
197	A Specialist Breast Care Nurse Role for Women With Metastatic Breast Cancer: Enhancing Supportive Care. <i>Oncology Nursing Forum</i> , 2011, 38, 627-631.	1.2	13
198	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 197-211.	1.1	13

#	ARTICLE	IF	CITATIONS
199	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017, 123, 985-993.	4.1	13
200	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5506-5506.	1.6	13
201	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj ETQq1 1 0.784314 rgBT14 Overlook	4.1	13
202	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	2.8	12
203	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathyâ€”a randomised controlled trial. <i>Supportive Care in Cancer</i> , 2021, 29, 1103-1110.	2.2	12
204	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. <i>Oncologist</i> , 2021, 26, 366-374.	3.7	12
205	Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3048-3048.	1.6	12
206	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 48-48.	1.6	12
207	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5503-LBA5503.	1.6	11
208	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.	3.3	11
209	Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. <i>International Journal of Cancer</i> , 2008, 123, 258-263.	5.1	10
210	Primary Surgical Management With Tailored Adjuvant Radiation for Stage IB2 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 765-772.	2.4	10
211	Medicareâ€”funded cancer genetic tests: a note of caution. <i>Medical Journal of Australia</i> , 2018, 209, 193-196.	1.7	10
212	Efficacy and safety of first-line veliparib and carboplatinâ€”paclitaxel in patients with HER2â€” advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	2.8	10
213	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5632-TPS5632.	1.6	10
214	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8457-8471.	1.9	10
215	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. <i>Gynecologic Oncology</i> , 2022, 165, 40-48.	1.4	10
216	A Fibroid or Cancer? A Rare Case of Mixed Choriocarcinoma and Epithelioid Trophoblastic Tumour. <i>Case Reports in Obstetrics and Gynecology</i> , 2013, 2013, 1-2.	0.3	9

#	ARTICLE	IF	CITATIONS
217	Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. <i>International Journal of Cancer</i> , 2019, 145, 370-379.	5.1	9
218	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021, 27, 4983-4993.	7.0	9
219	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	2.8	9
220	Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5542-5542.	1.6	9
221	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR) Tj ETQq1 1 0.784314 rgBT /Overlook 2016, 34, 5501-5501.	1.6	9
222	Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> and <i>BRCA2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110596.	3.2	9
223	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. <i>Gynecologic Oncology</i> , 2005, 97, 16-25.	1.4	8
224	Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment?. <i>Journal of Clinical Oncology</i> , 2011, 29, e553-e554.	1.6	8
225	Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 539-544.	1.8	8
226	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , 2021, 14, 983-994.	1.5	8
227	PARAGON: A phase 2 study of anastrozole (An) in patients with estrogen receptor(ER) and / progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5524-5524.	1.6	8
228	Current Academic Clinical Trials in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1290-1298.	2.5	7
229	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e81.	2.2	7
230	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	6.4	7
231	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	1.4	7
232	AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5518-5518.	1.6	7
233	A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5565-5565.	1.6	7
234	No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , 2004, 95, 430-436.	1.4	6

#	ARTICLE	IF	CITATIONS
235	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. Cancer Prevention Research, 2021, 14, 131-144.	1.5	6
236	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. Journal of Clinical Oncology, 2020, 38, 6068-6068.	1.6	6
237	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. Gynecologic Oncology, 2022, 164, 278-287.	1.4	6
238	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
239	Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecologic Oncology, 2021, 163, 398-407.	1.4	5
240	Should MMT still be treated with adjuvant taxane-based combination chemotherapy?. Journal of Cancer Research and Clinical Oncology, 2020, 146, 695-704.	2.5	5
241	Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903.. Journal of Clinical Oncology, 2016, 34, 5520-5520.	1.6	5
242	Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecologic Oncology, 2022, 166, 254-262.	1.4	5
243	Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 459-464.	1.1	4
244	Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878850.	3.2	4
245	Do all patients with recurrent ovarian cancer need systemic therapy?. Cancer, 2019, 125, 4602-4608.	4.1	4
246	Optimally Debulked Stage III Ovarian Cancer: Intraperitoneal or Intravenous Chemotherapy?. International Journal of Gynecological Cancer, 2010, 20, S20-S23.	2.5	4
247	A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK TRIAL.. Journal of Clinical Oncology, 2012, 30, TPS5116-TPS5116.	1.6	4
248	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. Journal of Clinical Oncology, 2015, 33, 9571-9571.	1.6	4
249	Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).. Journal of Clinical Oncology, 2016, 34, 5559-5559.	1.6	4
250	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. Journal of Clinical Oncology, 2018, 36, 10081-10081.	1.6	4
251	Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.. Journal of Clinical Oncology, 2019, 37, 5539-5539.	1.6	4
252	Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. JNCI Cancer Spectrum, 2021, 5, pkaa110.	2.9	4

#	ARTICLE	IF	CITATIONS
253	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. Cancer Investigation, 1999, 17, 479-485.	1.3	3
254	Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology, 2006, 38, 145-151.	0.6	3
255	Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hereditary Cancer in Clinical Practice, 2007, 5, 161.	1.5	3
256	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 2007, 6, 578-582.	2.3	3
257	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology, 2021, 161, 502-507.	1.4	3
258	Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).. Journal of Clinical Oncology, 2012, 30, 5081-5081.	1.6	3
259	Predictors of resilience in women treated for breast cancer: A prospective study.. Journal of Clinical Oncology, 2012, 30, 9044-9044.	1.6	3
260	PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.. Journal of Clinical Oncology, 2013, 31, TPS5614-TPS5614.	1.6	3
261	Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, TPS1102-TPS1102.	1.6	3
262	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3066-3066.	1.6	3
263	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology, 2022, , JCO2102108.	1.6	3
264	The value of participating in clinical trials: the whole is greater than the sum of its parts. Medical Journal of Australia, 2018, 209, 424.	1.7	2
265	Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. European Journal of Cancer, 2021, 148, 251-259.	2.8	2
266	392â€¦Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study. , 2020, , .		2
267	Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy.. Journal of Clinical Oncology, 2015, 33, 5547-5547.	1.6	2
268	Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).. Journal of Clinical Oncology, 2016, 34, 5575-5575.	1.6	2
269	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. Journal of Clinical Oncology, 2018, 36, 10062-10062.	1.6	2
270	Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative g<i>BRCA</i>-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.. Journal of Clinical Oncology, 2020, 38, 1097-1097.	1.6	2

#	ARTICLE	IF	CITATIONS
271	PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).. Journal of Clinical Oncology, 2020, 38, 6077-6077.	1.6	2
272	The Ovarian cancer Prognosis And Lifestyle (OPAL) study.. Journal of Clinical Oncology, 2018, 36, 88-88.	1.6	2
273	Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.. Journal of Clinical Oncology, 2020, 38, 6014-6014.	1.6	2
274	Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 2022, , .	1.4	2
275	Interobserver and intraobserver variability of RECIST assessment in ovarian cancer. International Journal of Gynecological Cancer, 2022, 32, 656-661.	2.5	2
276	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer, 2022, 170, 169-178.	2.8	2
277	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Medical Ethics, 2016, 17, 63.	2.4	1
278	Resisting RECISTâ€™Uniformity Versus Clinical Validity. International Journal of Gynecological Cancer, 2017, 27, 1619-1627.	2.5	1
279	Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. Journal of the National Cancer Institute, 2020, 112, 418-422.	6.3	1
280	Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. Journal of Clinical Oncology, 2021, 39, 5584-5584.	1.6	1
281	Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.. Journal of Clinical Oncology, 2012, 30, 4531-4531.	1.6	1
282	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. Journal of Clinical Oncology, 2013, 31, 9602-9602.	1.6	1
283	Molecular profiling of clear cell ovarian carcinoma.. Journal of Clinical Oncology, 2014, 32, 5516-5516.	1.6	1
284	Characterization of ovarian cancer long-term responders on olaparib.. Journal of Clinical Oncology, 2014, 32, 5534-5534.	1.6	1
285	Risk of uterine cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.. Journal of Clinical Oncology, 2016, 34, 1529-1529.	1.6	1
286	Inter and intra-observer variability with the assessment of RECIST in ovarian cancer.. Journal of Clinical Oncology, 2018, 36, 5555-5555.	1.6	1
287	Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.. Journal of Clinical Oncology, 2018, 36, 445-445.	1.6	1
288	Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.. Journal of Clinical Oncology, 2020, 38, 1091-1091.	1.6	1

#	ARTICLE	IF	CITATIONS
289	The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.. Journal of Clinical Oncology, 2014, 32, TPS5627-TPS5627.	1.6	1
290	Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ GCIG/PoCoG).. Journal of Clinical Oncology, 2014, 32, TPS5615-TPS5615.	1.6	1
291	Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology, 2016, 34, 5508-5508.	1.6	1
292	Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).. Journal of Clinical Oncology, 2017, 35, 5575-5575.	1.6	1
293	Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.. Journal of Clinical Oncology, 2018, 36, 5556-5556.	1.6	1
294	REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).. Journal of Clinical Oncology, 2018, 36, 10097-10097.	1.6	1
295	Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. Cancer Treatment and Research Communications, 2022, 30, 100504.	1.7	1
296	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. JNCI Cancer Spectrum, 2021, 5, pkab090.	2.9	1
297	Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.. Journal of Clinical Oncology, 2022, 40, 6518-6518.	1.6	1
298	CURRENT GENITOURINARY CANCER SURGERY. Australian and New Zealand Journal of Medicine, 1991, 21, 492-492.	0.5	0
299	A response to the forgotten fallopian tube. Nature Reviews Cancer, 2011, 11, 227-227.	28.4	0
300	Reply to M.G. McNamara et al and M.S. Copur et al. Journal of Clinical Oncology, 2015, 33, 2583-2584.	1.6	0
301	Tumour profiling for treatment of patients with ovarian cancers. Pathology, 2018, 50, S77.	0.6	0
302	Abstract PS11-03: Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: A subgroup analysis of germlineBRCA1orBRCA2mutations from the phase 3 BROCADE3 trial. , 2021, , .		0
303	1429Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer. International Journal of Epidemiology, 2021, 50, .	1.9	0
304	The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer. , 2021, , 43-53.		0
305	Squamous Cell Carcinomas Arising From Dermoids. , 2011, , 131-133.		0
306	Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned? , 2014, , 91-100.		0

#	ARTICLE	IF	CITATIONS
307	The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.. Journal of Clinical Oncology, 2014, 32, TPS5621-TPS5621.	1.6	0
308	Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.. Journal of Clinical Oncology, 2016, 34, e16056-e16056.	1.6	0
309	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. Journal of Clinical Oncology, 2017, 35, TPS4592-TPS4592.	1.6	0
310	Should MMT of the endometrium/ovary be treated with anthracycline instead of taxane based chemotherapy?. Journal of Clinical Oncology, 2017, 35, 5563-5563.	1.6	0
311	Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).. Journal of Clinical Oncology, 2017, 35, 1104-1104.	1.6	0
312	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2018, 36, TPS574-TPS574.	1.6	0
313	The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.. Journal of Clinical Oncology, 2018, 36, 155-155.	1.6	0
314	When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.. Journal of Clinical Oncology, 2018, 36, 172-172.	1.6	0
315	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. Journal of Clinical Oncology, 2018, 36, TPS4596-TPS4596.	1.6	0
316	Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.. Journal of Clinical Oncology, 2018, 36, 5568-5568.	1.6	0
317	How long have we got? The accuracy of physicians' estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, 5549-5549.	1.6	0
318	Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline <i>BRCA</i> Pathogenic Variants: A Cause for Concern or Potentially Avoidable?. Journal of Clinical Oncology, 2022, , JCO2200325.	1.6	0
319	Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003009.	2.5	0
320	Abstract LB511: The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab. Cancer Research, 2022, 82, LB511-LB511.	0.9	0